Ahn-Gook Pharmaceutical Co., Ltd.
Financials
Valuation Metrics
Ahn-Gook Pharmaceutical Co., Ltd.'s Market Cap is ₩1233B. At end of 2025 it was ₩1103B. Ranked #1087 of 2,405 in KR market (top 45%), #562 of 1,627 on KOSDAQ (top 35%), #126 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 55%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 123.25B KRW | KR#1,087/2,405 Sec#126/231 |
| Revenue | 345.08B KRW | KR#776/2,405 Sec#36/231 |
| Net Income | 21.71B KRW | KR#673/2,405 Sec#46/231 |
| Total Assets | 310.95B KRW | KR#1,014/2,405 Sec#66/231 |
| Net Assets | 166.29B KRW | KR#1,067/2,405 Sec#75/231 |
| Employees | 420 | KR#580/2,405 Sec#47/231 |
| Value | ||
| P/E | 5.68x | KR#486/2,405 Sec#20/231 |
| P/B | 0.74x | KR#1,251/2,405 Sec#74/231 |
| P/S | 0.36x | KR#745/2,405 Sec#22/231 |
| EV/EBITDA | 6.63x | KR#398/2,405 Sec#15/231 |
| FCF Yield | 30.20% | KR#209/2,405 Sec#4/231 |
| Profitability | ||
| ROE | 13.06% | KR#411/2,405 Sec#28/231 |
| ROA | 6.98% | KR#517/2,405 Sec#41/231 |
| Op. Margin | 6.86% | KR#739/2,405 Sec#60/231 |
| Revenue Growth | 18.68% | KR#583/2,405 Sec#55/231 |
| Financial Health | ||
| Debt Ratio | 86.99% | KR#1,423/2,405 Sec#166/231 |
| Total Debt | 72.48B KRW | KR#848/2,405 Sec#58/231 |
| FCF | 37.22B KRW | KR#354/2,405 Sec#20/231 |
| Cash | 38.95B KRW | KR#868/2,405 Sec#56/231 |
| Current Ratio | 1.69x | KR#1,040/2,405 Sec#118/231 |
| Net Debt/EBITDA | 1.42x | KR#779/2,405 Sec#53/231 |
| Dividend | ||
| Div. Yield | 6.70% | KR#162/2,405 Sec#2/231 |
| Div. Growth | 43.86% | KR#273/2,405 Sec#13/231 |
| Performance | ||
| 1Y Return | 20.38% | KR#306/2,405 Sec#19/231 |
| 1M Return | -3.67% | KR#582/2,405 Sec#57/231 |
| From 52W High | -30.77% | KR#436/2,405 Sec#27/231 |
| 1Y MDD | -30.64% | KR#256/2,405 Sec#16/231 |
| Trading | ||
| Volume | 19,790 shares | KR#1,492/2,405 Sec#145/231 |
| Trading Value | 187.4M KRW | KR#1,158/2,405 Sec#132/231 |
| Foreign Own. | 4.38% | KR#967/2,405 Sec#86/231 |
| Per Share | ||
| EPS | 1,665 KRW | KR#509/2,405 Sec#34/231 |
| BPS | 12,750 KRW | KR#812/2,405 Sec#54/231 |
Company Info
Anguk Pharmaceutical, established in 1959, manufactures and sells pharmaceuticals and health functional foods, having been listed on the KOSDAQ market in 2000. It holds several competitive drugs, including Cinechura, Revotension, Revosartan, and Fevarojet, specializing in antitussive expectorant and circulatory system medications. Its Hanam-eup, Hwaseong-si plant, certified by GMP, ensures the production of high-quality pharmaceuticals and engages in contract manufacturing organization (CMO) to maintain stable supply. Anguk Pharmaceutical is headquartered in Gwacheon-si, Gyeonggi-do.